Valeant invests $8M in Manitoba manufacturing plant
Company to transfer North American production of Xifaxan and Apriso to Steinbach facility.
LAVAL, Que. — Valeant Canada has announced an $8 million investment in its Steinbech, Man. manufacturing plant.
The pharmaceutical manufacturing will complete the transfers of the North American production of Xifaxan and Apriso this year to the Steinbach facility.
The plant is the company’s largest in North American, which handles all of the company’s manufacturing of controlled-release products. Each year, the facility, which has more than 400 employees, produces and packages 1.2 billion tablets or capsules of different kinds of medications which are sold worldwide to treat pain, high blood pressure and depression.
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International Inc., a multinational specialty pharmaceutical manufacturer.